XHANCE – Talk Bio

Actionable Insights Powered by AI

Paratek Expands into Chronic Rhinosinusitis Market with $330M Optinose Acquisition

Paratek Pharmaceuticals, Optinose , XHANCE, Chronic rhinosinusitis, Nasal drug delivery, Pharmaceutical acquisition, Specialty pharma